In this article, we will look at the 10 Best Penny Stocks to Buy Before They Explode.
Penny stocks tend to attract attention when risk appetite improves, and smaller companies start participating in the market rally. These stocks can move sharply when expectations are low, liquidity improves, or a business shows early signs of an earnings turn. Franklin Templeton says “2026 could be the year that small-caps reassert themselves,” while also noting that “both small-cap quality and value are poised for meaningful rebounds in 2026.” That matters for penny stocks because many of them sit at the speculative end of the small-cap universe.
The broader small-cap backdrop is helping the argument. AllianceBernstein says “Earnings growth, for example, is expected to outstrip those for large companies in 2026” and adds that “small-cap earnings could be widely underestimated by the market.” In summary, the setup is not just about low prices. It is about whether the market has become too pessimistic on smaller companies that may be entering a better earnings cycle. T. Rowe Price makes a similar point, arguing that “the small-cap rebound has not been driven by sentiment alone” because “fundamentals also have turned” and small-cap earnings began to rapidly improve in late 2025.
Against this backdrop, the penny stocks worth watching are not simply the lowest-priced names on the market. The more interesting candidates are those with improving fundamentals, visible catalysts, analyst support, or exposure to themes where investor attention can return quickly. With that in mind, let’s take a look at the 10 Best Penny Stocks to Buy Before They Explode.
Our Methodology
We used the Finviz screener to identify stocks that are trading below $5 per share and offer significant upside from analysts’ price targets. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. Playtika Holding Corp. (NASDAQ:PLTK)
On May 7, 2026, Playtika Holding Corp. (NASDAQ:PLTK) reported Q1 EPS of (15c), versus the consensus estimate of 12c. Revenue totaled $744.7M, versus the consensus estimate of $694.65M. CEO Robert Antokol said the company delivered a strong start to 2026, driven by continued momentum in Disney Solitaire and another record quarter for its direct-to-consumer business. Antokol also said management is seeing signs of improving stability across the broader organic portfolio and remains focused on disciplined execution and long-term engagement growth. CFO Tae Lee said first-quarter performance exceeded prior expectations, with SuperPlay tracking ahead of plan and the core portfolio showing strength. Lee added that adjusted EBITDA reflected a planned front-loaded investment cycle tied to the scaling of SuperPlay, which is expected to normalize over the course of the year.
Playtika Holding Corp. raised its FY26 revenue outlook to $2.75B-$2.85B from $2.7B-$2.8B, versus the consensus estimate of $2.77B.
Last month, Playtika Holding Corp. announced that a special committee of independent directors is conducting a strategic review of alternatives across the company’s portfolio as part of efforts to enhance shareholder value. The committee retained Morgan Stanley & Co. as financial advisor to evaluate potential opportunities and alternatives, though the company said there is no assurance the process will result in a transaction.
Playtika Holding Corp., through its subsidiaries, develops mobile games across global markets.
9. Evotec SE (NASDAQ:EVO)
On May 4, 2026, Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance with Almirall focused on medical dermatology. The program is aimed at developing new therapies for immune-mediated inflammatory skin diseases with significant unmet medical needs. Evotec SE said it will continue supporting the program toward IND submission through its INDiGO platform, which is designed to accelerate the transition from discovery through clinical readiness.
On April 30, 2026, Evotec SE also announced that it received two additional grants from the Gates Foundation for tuberculosis drug discovery and translation programs. The grants follow four earlier TB-related awards from the foundation and total approximately $4.9M over 25 months and $5M over 24 months. The company said the programs are intended to expand the pipeline of tuberculosis drug candidates and advance the most promising combinations toward clinical evaluation while helping reduce development risk.
Earlier in April, H.C. Wainwright assumed coverage on Evotec SE with a Buy rating and a $7 price target. The firm said the company has been transitioning away from a more asset-heavy integrated structure toward a leaner and more capital-efficient operating model, adding that current share levels appear attractive for long-term investors.
Evotec SE operates as a drug discovery and development company across the United States, Europe, and other international markets.
8. MannKind Corporation (NASDAQ:MNKD)
On May 7, 2026, Wells Fargo raised the firm’s price target on MannKind Corporation (NASDAQ:MNKD) to $10 from $8 while maintaining an Overweight rating following disclosure of the company’s involvement with ralinepag DPI and ahead of upcoming PDUFA decisions tied to Afrezza and Furoscix. The firm said it now sees multiple potential avenues for revenue growth.
Similarly, H.C. Wainwright raised its price target on MannKind Corporation to $10 from $8 while maintaining a Buy rating. The firm said Q1 results came in below expectations, though that does not alter its broader investment thesis, which is increasingly centered on the durability and upside potential of MannKind’s royalty and collaboration revenue streams. H.C. Wainwright also cited potential pipeline upside in support of the target increase.
A day earlier, MannKind Corporation reported Q1 EPS of (2c), versus the consensus estimate of 1c. Revenue totaled $90.17M, versus the consensus estimate of $105.31M. CEO Michael Castagna said the company continues making progress on its corporate transformation strategy focused on expanding and diversifying both its commercial portfolio and development pipeline. Castagna described 2026 as the most catalyst-rich year in MannKind’s history. Castagna added that potential approval of the Furoscix ReadyFlow Autoinjector could help accelerate the brand’s growth trajectory, while a potential pediatric expansion for Afrezza could address unmet needs in a new patient population. Castagna also pointed to continued momentum from Tyvaso DPI, including expansion into IPF, along with the company’s expanded collaboration with United Therapeutics involving ralinepag DPI.
MannKind Corporation is a biopharmaceutical company focused on developing therapies and technologies for chronic disease care.
7. Prime Medicine, Inc. (NASDAQ:PRME)
On May 7, 2026, Prime Medicine, Inc. (NASDAQ:PRME) reported Q1 EPS of (28c), versus the consensus estimate of (25c). Revenue totaled $856,000, versus the consensus estimate of $844,220. Chief Executive Officer Allan Reine said that the company continues to execute on a focused strategy aimed at advancing the potential of Prime Editing. Reine added that Prime Medicine remains on track to file regulatory applications for PM577 in Wilson Disease during the first half of the year and for PM647 in alpha-1 antitrypsin deficiency mid-year, with initial data from both programs expected in 2027. Reine also said the company continues progressing toward a potential BLA filing for PM359, which is being developed as a one-time therapy for chronic granulomatous disease. According to Reine, Prime Medicine, Inc. believes its strengthened leadership team and disciplined capital allocation strategy position the company to continue advancing its broader pipeline.
Last month, Prime Medicine, Inc. announced the appointment of Svetlana Makhni as Chief Financial Officer. Makhni will oversee the company’s financial operations and strategy, including investor relations, financial planning and analysis, and corporate development.
Prime Medicine, Inc. is a biotechnology company developing genetic medicines using Prime Editing technology.
6. Nuvation Bio Inc. (NYSE:NUVB)
On May 6, 2026, Nuvation Bio Inc. (NYSE:NUVB) announced that the U.S. FDA accepted a supplemental New Drug Application containing updated data for IBTROZI in both TKI-naive and TKI-pretreated advanced ROS1-positive non-small cell lung cancer. The FDA assigned a target action date of January 4, 2027.
On May 4, 2026, Nuvation Bio Inc. reported Q1 EPS of 1c, versus the consensus estimate of 5c. Revenue totaled $83.23M, versus the consensus estimate of $62.34M. Founder, President, and CEO David Hung said the company continues to see positive launch trends for IBTROZI as adoption expands across additional lines of therapy in advanced ROS1-positive NSCLC. Hung also highlighted updated long-term follow-up data presented at AACR showing durability exceeding four years in TKI-naive patients, which management believes further supports physician confidence in the treatment. Hung added that Nuvation recently secured exclusive global development and commercialization rights to safusidenib and plans to advance the Phase 3 SIGMA study in high-risk IDH1-mutant glioma. The company also expects to provide updates later this year on its drug-drug conjugate platform.
Last month, Nuvation Bio Inc. announced updated pooled long-term follow-up data from the pivotal TRUST-I and TRUST-II trials evaluating IBTROZI, also known as taletrectinib, in advanced ROS1-positive NSCLC patients. The data were presented at the AACR Annual Meeting 2026 and included both oral and poster presentations. In TKI-naive patients, pooled data showed a confirmed objective response rate of 89.8%, median duration of response of 49.7 months, and median progression-free survival of 46.1 months. The company also reported an intracranial response rate of 76.5% among patients with brain metastases.
For TKI-pretreated patients, pooled results showed a confirmed objective response rate of 55.8%, a median duration of response of 16.6 months, a median progression-free survival of 9.7 months, and an intracranial response rate of 65.6% in patients with brain metastases. The company said pooled safety data remained consistent with the current prescribing profile, with treatment discontinuation rates due to treatment-emergent adverse events remaining low at 8.5%. No new safety signals were identified during longer-term follow-up.
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies.
5. Ocugen, Inc. (NASDAQ:OCGN)
On May 5, 2026, Ocugen, Inc. (NASDAQ:OCGN) reported Q1 EPS of (6c), versus the consensus estimate of (5c). Revenue totaled $1.53M, versus the consensus estimate of $358,140. Chairman, CEO, and Co-Founder Dr. Shankar Musunuri said the company completed enrollment in two late-stage programs during the first few months of 2026 and is continuing preparations toward initiating its first BLA submission for retinitis pigmentosa and a registration trial for dry AMD later this year. Musunuri also said Ocugen believes it is executing efficiently against its strategic plans, citing productivity levels, recent financing activity, and milestone progress aimed at supporting long-term value creation.
A day earlier, Ocugen, Inc. announced plans to offer, subject to market conditions and other factors, $115M aggregate principal amount of convertible senior notes due 2034 in a private offering to qualified institutional buyers under Rule 144A of the Securities Act.
Last month, Ocugen, Inc. announced that dosing was completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial evaluating OCU410ST for Stargardt disease. The company said the trial represents its second late-stage clinical program and added that it plans to submit a BLA for OCU410ST by mid-2027 as part of its broader goal of filing three BLAs by 2028.
Ocugen, Inc. is a biopharmaceutical company focused on developing and commercializing gene therapies, cell therapies, biologics, and vaccines.
4. Clean Energy Fuels Corp. (NASDAQ:CLNE)
On May 7, 2026, Clean Energy Fuels Corp. (NASDAQ:CLNE) reported Q1 adjusted EPS of (1c), versus the consensus estimate of (3c). Revenue totaled $117.56M, versus the consensus estimate of $97.85M. The company said renewable natural gas volumes continued to recover from last year despite weather-related disruptions affecting dairy RNG production, particularly in the upper Midwest. Management added that operating refinements across the industry are helping improve production consistency, while newer projects such as the East Valley facility in Idaho and the South Fork project in Texas are continuing to ramp up output. Clean Energy Fuels Corp. also said higher oil and diesel prices following the conflict in Iran have increased interest in its natural gas transportation fuel offerings, which management described as less volatile than diesel. The company added that results during the quarter reflected some benefits from elevated diesel pricing against a relatively stable natural gas commodity backdrop.
On May 4, 2026, Clean Energy Fuels Corp. announced the expansion of its renewable natural gas fueling network with six new stations across California, New Jersey, Oklahoma, Michigan, and Washington. The stations are positioned along major freight transportation corridors and are intended to support growing adoption of Cummins’ X15N natural gas engine for heavy-duty trucking applications. The company said the new locations expand its network of more than 600 fueling stations across North America, serving transit, refuse, municipal, airport, and trucking fleets.
Last month, Clean Energy Fuels Corp. announced the appointment of Clay Corbus as President and Chief Executive Officer, effective immediately. Corbus also joined the company’s board of directors, succeeding co-founder Andrew Littlefair, who led the company for 30 years. Littlefair transitioned from the CEO role to serve as a non-employee government relations consultant while remaining on the board.
Clean Energy Fuels Corp. provides natural gas transportation fuels and fueling solutions for vehicle fleets across the United States and Canada.
3. The Real Brokerage Inc. (NASDAQ:REAX)
On May 8, 2026, B. Riley analyst Naved Khan lowered the firm’s price target on The Real Brokerage Inc. (NASDAQ:REAX) to $7 from $8 while maintaining a Buy rating. The firm said it viewed the company’s Q1 results positively.
On May 7, 2026, The Real Brokerage Inc. reported Q1 EPS of (2c). Revenue totaled $465.6M, versus the consensus estimate of $481.87M. Chairman and CEO Tamir Poleg said the company delivered another quarter of strong growth, with revenue increasing 32% year over year, reflecting continued momentum in its platform and agent value proposition. Poleg also described the planned acquisition of RE/MAX Holdings as a transformative event for both the company and the broader real estate industry.
On April 27, 2026, The Real Brokerage Inc. and RE/MAX Holdings, Inc. announced a definitive agreement under which Real will acquire RE/MAX Holdings to create a combined technology-enabled real estate platform called Real REMAX Group. The transaction implies an enterprise value for RE/MAX Holdings of approximately $880M and is expected to be accretive to Real’s earnings and adjusted EBITDA margin within the first full fiscal year after closing, excluding integration-related costs. The companies said the deal combines Real’s AI-driven brokerage platform and proprietary software with the RE/MAX global franchise network spanning more than 120 countries and territories and more than 145,000 agents. The combined company is expected to support more than 180,000 agents globally and generate approximately $2.3B in annual revenue and $157M in adjusted EBITDA on a pro forma 2025 basis before synergies.
The companies also expect approximately $30M in annual run-rate cost savings, primarily from shared services, technology efficiencies, and corporate costs, with most of the savings expected by 2027. Following the transaction, Poleg is expected to serve as Chairman and CEO of Real REMAX Group. The combined company is expected to remain listed on Nasdaq under the ticker REAX and headquartered in Miami, while maintaining significant operations in Denver. The transaction is expected to close in the second half of 2026, subject to shareholder approvals, regulatory clearances, and customary closing conditions.
The Real Brokerage Inc. operates as a real estate technology company in the United States and Canada.
2. Pacific Biosciences of California, Inc. (NASDAQ:PACB)
On May 7, 2026, Pacific Biosciences of California, Inc. (NASDAQ:PACB) reported Q1 EPS of (12c), versus the consensus estimate of (13c). Revenue totaled $37.18M, versus the consensus estimate of $39.98M. President and CEO Christian Henry said the company continued to see increasing clinical adoption of HiFi, contributing to another record quarter for consumables revenue, though instrument revenue, particularly from Vega, came in below expectations. Henry added that PacBio made progress on several initiatives, including the expansion of the SPRQ-Nx beta program following positive early feedback on the new chemistry. Based on those results, the company plans a broader commercial rollout to all Revio customers later this month, which management believes could further support consumables growth and Revio demand. Henry also noted that PacBio was selected by Basecamp Research to support the Trillion Gene Atlas project, which could become the world’s largest and most diverse high-fidelity metagenomic dataset. PacBio sees FY26 revenue of $165M-$175M, versus the consensus estimate of $174.42M.
Last month, Pacific Biosciences of California, Inc. and Lucid Genomics announced that Lucid Genomics joined the PacBio Compatible partner program as a tertiary analysis solution for data generated using PacBio long-read sequencing platforms. Lucid Genomics Founder and CEO Dr. Uira Souto Melo said the designation marks an important milestone for both the company and its users, adding that long-read sequencing continues to unlock genomic regions and patterns that were previously difficult to analyze.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing technologies used to address genetically complex challenges.
1. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
On May 7, 2026, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported Q1 EPS of (19c), versus the consensus estimate of (15c). Revenue totaled $71.43M, versus the consensus estimate of $75.66M. Interim President and Chief Executive Officer Frederick Vogt said the company is accelerating commercial adoption and expansion of Amtagvi following record demand levels. Vogt added that Iovance remains positioned for long-term revenue growth through 2026 while continuing to advance several ongoing and new clinical programs, including its registrational sarcoma trial and recently reported initial data for lifileucel in metastatic serous endometrial cancer. Vogt also said internal manufacturing efficiencies, operational improvements, and cost reduction efforts are expected to support gross margin expansion and future profitability.
Iovance Biotherapeutics, Inc. said it expects Q2 revenue of $86M-$88M, versus the consensus estimate of $84.36M. The company also maintained FY26 revenue guidance of $350M-$370M, versus the consensus estimate of $359.68M.
Following the earnings report, Chardan lowered its price target on Iovance Biotherapeutics, Inc. to $14 from $16 while maintaining a Buy rating. The firm said it updated its model to reflect revised launch expectations for Amtagvi.
Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor-infiltrating lymphocyte cell therapies for metastatic melanoma and other solid tumor cancers.
READ NEXT: 10 AI Stocks with Potential to Rise 1000 Percent and 10 Best AI Pick-and-Shovel Stocks to Buy
